In the context of adoptive cell therapy (ACT) targeting the tumor immune microenvironment, increasing CD8+ effector T cells within tumor-infiltrating lymphocytes (TILs) has been shown to enhance therapeutic outcomes (7). Here, CD8A is linked to neoplasm.